CSH2 and SHORT syndrome: Noticeably, most of the SHORT syndrome-linked mutations targeted a cSH2 residue or introduced a stop codon at the cSH2 domain, suggesting a dispensable role for the p85α cSH2 domain in the direct control of p110α activity.